From: Order effects: a randomised study of three major cancer-specific quality of life instruments
Variable | Questionnaire Package | |||||||
---|---|---|---|---|---|---|---|---|
EORTC QLQ-C30 + FACT-G (N = 200) | FACT-G + EORTC QLQ-C30(N = 240) | EORTC QLQ-C30 + FLIC (N = 233) | FLIC + EORTC QLQ-C30 (N = 188) | FACT-G + FLIC (N = 215) | FLIC + FACT-G (N = 201) | p-value(a) | ||
Age | Mean (SD) | 51.0 (12.0) | 51.6 (12.5) | 50.6 (9.9) | 51.0 (10.3) | 51.4 (10.5) | 51.4 (11.6) | 0.933 |
Gender | Male | 43.5% | 40.8% | 36.1% | 41.0% | 43.7% | 38.3% | 0.547 |
Female | 56.5% | 59.2% | 64.0% | 59.0% | 56.3% | 61.7% | ||
Race | Chinese | 88.0% | 91.3% | 90.6% | 91.0% | 90.7% | 89.1% | 0.446 |
Malay | 6.5% | 4.6% | 3.4% | 2.7% | 3.7% | 4.5% | ||
Indian | 4.0% | 3.8% | 3.0% | 4.3% | 2.3% | 5.5% | ||
Others | 1.5% | 0.4% | 3.0% | 2.1% | 3.3% | 1.0% | ||
Education | Primary or below | 22.1% | 20.4% | 21.0% | 19.2% | 23.8% | 21.9% | 0.212 |
Secondary | 44.7% | 43.8% | 49.4% | 57.9% | 45.3% | 47.8% | ||
Post-secondary | 33.2% | 35.8% | 29.6% | 22.9% | 30.8% | 30.4% | ||
ECOG | 0–1 | 75.5% | 72.5% | 75.1% | 71.8% | 69.8% | 72.0% | 0.772 |
2–4 | 24.5% | 27.5% | 24.9% | 28.2% | 30.2% | 28.0% | ||
Treatment | Inactive | 59.0% | 69.6% | 59.2% | 61.7% | 60.9% | 62.7% | 0.186 |
Active | 41.0% | 30.4% | 40.8% | 38.3% | 39.1% | 37.3% | ||
Tumor | Breast | 30.5% | 33.8% | 40.8% | 33.0% | 33.0% | 34.8% | 0.719 |
Lung | 7.5% | 8.3% | 5.6% | 6.4% | 9.8% | 10.0% | ||
Colo-rectal | 14.5% | 10.8% | 12.0% | 13.8% | 13.5% | 11.9% | ||
Gynaecological | 5.0% | 5.8% | 3.4% | 9.0% | 4.7% | 6.5% | ||
Nasopharyngeal | 13.5% | 13.3% | 12.5% | 13.3% | 14.4% | 16.4% | ||
Head & Neck | 8.0% | 5.8% | 5.2% | 5.9% | 5.1% | 7.00% | ||
Others | 21.0% | 22.1% | 20.6% | 18.6% | 19.5% | 13.4% | ||
Self-administered | Yes | 76.5% | 79.6% | 76.8% | 75.5% | 75.4% | 73.1% | 0.738 |
No | 23.5% | 20.4% | 23.2% | 24.5% | 24.7% | 26.9% | ||
Language | English | 57.5% | 56.7% | 49.8% | 51.1% | 60.0% | 57.2% | 0.219 |
Chinese | 42.5% | 43.3% | 50.2% | 48.9% | 40.0% | 42.8% |